Currently out of the existing stock ratings of Biren Amin, 249 are a BUY (85.57%), 42 are a HOLD (14.43%).

Biren Amin

Work Performance Price Targets & Ratings Chart

Analyst Biren Amin, currently employed at PIPER SANDLER, carries an average stock price target met ratio of 54.84% that have a potential upside of 34.13% achieved within 237 days.

Biren Amin’s has documented 582 price targets and ratings displayed on 68 stocks. The coverage is on Healthcare, Consumer Cyclical sectors.

Most recent stock forecast was given on NERV, Minerva Neurosciences at 14-Aug-2026.

Wall Street Analyst Biren Amin

Analyst best performing recommendations are on GRCL (GRACELL BIOTECHNOLOGIES).
The best stock recommendation documented was for ZNTL (ZENTALIS PHARMACEUTICALS LLC) at 5/18/2020. The price target of $44 was fulfilled within 1 day with a profit of $4.35 (10.97%) receiving and performance score of 109.71.

Average potential price target upside

of $1150.94 (27.43%) on TRVN (TREVENA).
of $68.53 (12.67%) on REGN (REGENERON PHARMACEUTICALS).
of $30.9 (16.85%) on CLDX (CELLDEX THERAPEUTICS).

AGEN Agenus ALKS Alkermes Plc ALLO Allogene Therapeutics BLCM Bellicum Pharmaceuticals BLUE Bluebird bio CCCC C4 Therapeutics CRTX Cortexyme FATE Fate Therapeutics HRTX Heron Therapeuti IMGN ImmunoGen MDCO The Medicines Company NBIX Neurocrine Biosciences NLNK NewLink Genetics REGN Regeneron Pharmaceuticals TRVN Trevena CLDX Celldex Therapeutics ACRX AcelRx Pharmaceuticals ANAB AnaptysBio CTMX CytomX Therapeutics IOVA Iovance Biotherapeutics LUMO Lumos Pharma KDMN Kadmon Holdings ZYNE Zynerba Pharmaceuticals STML Stemline Therapeutics XENE Xenon Pharmaceuticals ARDX Ardelyx GLYC GlycoMimetics KALA Kala Pharmaceuticals NK NantKwest OBSV ObsEva SA VSTM Verastem NERV Minerva Neurosciences ZNTL Zentalis Pharmaceuticals Llc ADVM Adverum Biotechnologies ACLX Arcellx APLS Apellis Pharmaceuticals IMNM Immunome SRPT Sarepta Therapeutics VKTX Viking Therapeutics CRGX CARGO Therapeutics, Common Stock ARCT Arcturus Therapeutics Holdings BBIO BridgeBio Pharma BCYC Bicycle Therapeutics Ltd CLLS Cellectis SA EQ Equillium IBRX Immunitybio IMTX Immatics NV LEGN Legend Biotech Corp NLTX Neoleukin Therapeutics MNPR Monopar Therapeutics OCUL Ocular Therapeutix SLDB Solid Biosciences LLC CNTX Context Therapeutics CAL Caleres CMPX Compass Therapeutics CNTA Centessa Pharmaceuticals PLC ADR GRCL Gracell Biotechnologies LENZ LENZ Therapeutics MD Mednax MRTX Mirati Ther TSHA Taysha Gene Therapies BCAB Bioatla ACRS Aclaris Therapeutics CATX Perspective Therapeutics CRBP Corbus Pharmaceuticals IGMS IGM Biosciences NRIX Nurix Therapeutics XOMA XOMA Corp

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Andreas Argyrides (CHARDAN CAPITAL)

Buy Since 18-Sep-2026

$40

$32.33 (421.51%)

$40

8 days ago
(05-Oct-2026)

0/2 (0%)

$31.27 (358.19%)

Please subscribe to see extended stock data

Michael King (RODMAN & RENSHAW)

Buy Since 17-Dec-2021

$19

$11.33 (147.72%)

15 days ago
(28-Sep-2026)

5/7 (71.43%)

$9.57 (101.48%)

474

Please subscribe to see extended stock data

Emily Bodnar (HC WAINWRIGHT)

Buy Since 08-Jul-2025

$25

$17.33 (225.95%)

$30

2 months 2 days ago
(11-Aug-2026)

7/17 (41.18%)

$18.17 (266.03%)

362

Please subscribe to see extended stock data

Mayank Mamtani (B.RILEY)

Buy Since 19-Nov-2019

$14

$6.33 (82.53%)

$160

2 months 13 days ago
(30-Jul-2026)

1/11 (9.09%)

$6.09 (76.99%)

633

Please subscribe to see extended stock data

Colleen Kusy (BAIRD)

Hold Since 12-Mar-2025

$2.97 (98.02%)

1 years 4 months 9 days ago
(04-Jun-2025)

2/2 (100%)

$0.37 (6.57%)

172

Please subscribe to see extended stock data

Show more analysts

Please expand the browser size to see the chart

Which stock is Biren Amin most bullish on?

Potential upside of $107.46 has been obtained for REGN (REGENERON PHARMACEUTICALS)

Which stock is Biren Amin most reserved on?

Potential downside of -$0.11 has been obtained for SRPT (SAREPTA THERAPEUTICS)

What Year was the first public recommendation made by Biren Amin?

On 2011